NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
Back to search
Official data from USPTO
EXCALIBUR PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
EXCALIBUR PHARMACEUTICALS
ST13
US500000088624847Class
5
Filing
88624847
Registration
7626610
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
56
Latest update
12/24/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
09/20/2019
Registration date
12/24/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
12/24/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/08/2022
First use in commerce
02/08/2022
Drawing code
4
Owner type
03
Owner location
New York, NY
Examiner
CANTONE, KERI
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Excalibur Pharmaceuticals, Inc.
Representatives
Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticaltherapeutic and biopharmaceutical agents for the treatment of fibrosiscirrhosisliver diseasekidney diseasedermatological conditions and diseasesautoimmune diseasesinflammatory diseasesNon-Alcoholic Fatty Liver DiseaseNon-Alcoholic Steatohepatitis (NASH)Capsular contracture; pharmaceuticaltherapeutic and biopharmaceutical preparations and substances for the treatment of fibrosiscirrhosisliver diseasekidney diseasedermatological conditions and diseasesautoimmune diseasesinflammatory diseasesNon-Alcoholic Fatty Liver DiseaseNon-Alcoholic Steatohepatitis (NASH)Capsular contracture; none of the foregoing for or related to the treatment of male erectile dysfunction
Publications
History of USPTO decisions and trademark events.
56 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/05/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2024
ALIE
ASSIGNED TO LIE
11/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/08/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/08/2024
GNRT
NON-FINAL ACTION E-MAILED
05/08/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
05/08/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/16/2024
IUAF
USE AMENDMENT FILED
04/08/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/08/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/06/2023
EX5G
SOU EXTENSION 5 GRANTED
09/05/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/05/2023
EXT5
SOU EXTENSION 5 FILED
08/28/2023
EEXT
SOU TEAS EXTENSION RECEIVED
08/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/06/2023
EX4G
SOU EXTENSION 4 GRANTED
04/04/2023
EXT4
SOU EXTENSION 4 FILED
04/04/2023
EEXT
SOU TEAS EXTENSION RECEIVED
04/04/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/08/2022
EX3G
SOU EXTENSION 3 GRANTED
10/06/2022
EXT3
SOU EXTENSION 3 FILED
10/06/2022
EEXT
SOU TEAS EXTENSION RECEIVED
10/06/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/08/2022
EX2G
SOU EXTENSION 2 GRANTED
04/06/2022
EXT2
SOU EXTENSION 2 FILED
04/06/2022
EEXT
SOU TEAS EXTENSION RECEIVED
04/06/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/01/2021
EX1G
SOU EXTENSION 1 GRANTED
09/29/2021
EXT1
SOU EXTENSION 1 FILED
09/29/2021
EEXT
SOU TEAS EXTENSION RECEIVED
09/29/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/09/2021
PUBO
PUBLISHED FOR OPPOSITION
02/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/20/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/06/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/10/2020
GNFR
FINAL REFUSAL E-MAILED
07/10/2020
CNFR
FINAL REFUSAL WRITTEN
07/10/2020
DMCC
DATA MODIFICATION COMPLETED
06/30/2020
ALIE
ASSIGNED TO LIE
06/29/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/05/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/02/2020
GNRT
NON-FINAL ACTION E-MAILED
01/02/2020
CNRT
NON-FINAL ACTION WRITTEN
01/02/2020
DOCK
ASSIGNED TO EXAMINER
12/20/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/26/2019
Continuous trademark protection
Get notified about every new filing that threatens EXCALIBUR PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.